Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 655-660

  Rodriguez, Carmen ^a   Feigelson, Heather Spencer ^a   Deka, Anusila ^a   Patel, Alpa V ^a   Jacobs, Eric J ^a   Thun, Michael J ^a   Calle, Eugenia E ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 41549111868     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2683     Document Type: Article

References (30)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007.
2. American Cancer Society. Cancer facts and figures 1996. Atlanta: American Cancer Society; 1996.
3. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997;89:1580-6.
4. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival: a population-based study of 20,561 cases. Ann Oncol 2002;13:1087-93.
5. Alexiou C, Onyeaka CV, Beggs D, et al. Do women live longer following lung cancer resection for carcinoma? Eur J Cardiothorac Surg 2002;21:319-25.
6. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78:209-15.
7. Chaudhuri PK, Thomas PA, Walker MJ, Briele HA, Das Gupta TK, Beattie CW. Steroid receptors in human lung cancer cytosols. Cancer Lett 1982;16:327-32.
8. Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors α and β in human lung tissue and cell lines. Lung cancer 2002;37:153-9.
9. Ishibashi H, Suzuki T, Suzuki S, et al. Progesterone receptor in nonsmall cell lung cancer - a potent prognostic factor and possible target for endocrine therapy. Cancer Res 2005;65:6450-8.
10. Taioli E, Wynder E. Re: endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994;86:869-70.
11. Liu Y, Inoue M, Sobue T, Tsugane S; for the JPHC Study Group. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer 2005;117:662-6.
12. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann H-E. Hormonal factors and risk of lung cancer among women? Int J Epidemiol 2003;32:263-71.
13. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004;10:113-23.
14. Ettinger B, Friedman GD, Bush T, Quesenberry CP. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6-12.
15. Olsson H, Bladstrom A, Ingvar C. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet Gynecol 2003;102:565-70.
16. Adami H-O, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989;44:833-9.
17. Blackman JA, Coogan PF, Rosenberg L, et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Safety 2002;11:561-7.
18. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
19. Wu AH, Yu MC, Thomas CC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1998;48:7279-84.
20. Elliot AM, Hannaford PC. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 2006;73:331-5.
21. Writting Group for the Women's Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
22. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 2004;291:47-53.
23. Drug Topics. Drugs by units in the United States in specific years. Available from: http://www.drugtopics.com/drugtopics/. Accessed 2007 Mar 29.
24. Calle EE. The American Cancer Society Nutrition Survey - rationale, study design, and baseline characteristics. Cancer 2002;94:500-11.
25. Garfinkel L. Selection, follow-up, and analysis in the American Cancer Society prospective studies. Monogr Natl Cancer Inst 1985;67:49-52.
26. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among Cancer Prevention Study II participants. Am J Epidemiol 1993;137:235-41.
27. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-3.
28. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982;42:3232-9.
29. Cagle PT, Mody DR, Schwartz MR. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res 1990;20:6632-5.
30. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007;72:135-43.